This pharmaceutical industry practice is hard to defend:

In a nutshell, the company that holds the patent on a profitable drug strikes a deal with the maker of the cheaper generic brand: you hold off on marketing your generic for several years, and in return, we'll give you a share of our profits on the drug.

We want to hear what you think about this article. Submit a letter to the editor or write to letters@theatlantic.com.